Press release
-
Press Release
BlueWhale Bio Announces First Patient Dosed in Clinical Trial Using Synecta™ T1 Cell-Derived Nanoparticles (CDNPs)
PHILADELPHIA, Sept. 3, 2025 /PRNewswire/ — BlueWhale Bio, a company dedicated to transforming immune cell therapy manufacturing, today announced that…
Read More »